Understanding Prograf Dosage Adjustments: Why Changes Happen

Tacrolimus (Prograf®) is a narrow-therapeutic-index immunosuppressant for transplant rejection prophylaxis. Dose adjustments are routine and individualized.

Reasons for Adjustment

• Therapeutic Drug Monitoring (TDM): Target trough levels (e.g., 5–15 ng/mL early post-kidney; lower later). Dose titrated to maintain window.
• Renal function: Nephrotoxicity (↑Cr, ↓GFR) → dose reduction. Distinguish from rejection (biopsy).
• Drug interactions: CYP3A4/P-gp inhibitors (azoles, macrolides, CCBs) ↑ levels → ↓ dose. Inducers (rifampin, phenytoin) ↓ levels → ↑ dose.
• Side effects: Neurotoxicity (tremor, headache, seizures), hyperglycemia, hypertension, electrolyte disturbances → dose reduction or switch.
• Transplant phase: High early (induction); taper over months as rejection risk drops.
• Adherence issues: Missed doses → erratic levels → adjustment + adherence counseling.
• Formulation change: IR (bid) vs. ER (once daily) not bioequivalent; requires conversion.

Patient Role

• Consistent timing (q12h for IR; same time daily for ER).
• Blood draws at trough (pre-dose).
• Report new meds, supplements, grapefruit, side effects immediately.
• Never adjust dose without transplant team.

Close collaboration between patient, coordinator, pharmacist, and physician optimizes graft survival and minimizes toxicity.